Active substance
Dexpanthenol
- SFDA 10
- NHS prices 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DEXANOL CREAM 30 GM | 5 % | Cream · Topical | 1 Tube | SAR 7.25 | Generic · OTC | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| DEXIPAN 5% CREAM | 5 % | Cream · Topical | 1 Tube | SAR 5.90 | NCE · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BEPANTHEN | 5 % | Ointment · Topical | 1 Tube | SAR 11.85 | Generic · OTC | GP GRENZACH | Withdrawn by MAH · Not Marketed |
| BEPANTHEN | 5 % | Cream · Topical | 1 Tube | SAR 12.30 | Generic · OTC | GP GRENZACH | Withdrawn by MAH · Not Marketed |
| BEPANTHEN | 5 % | Ointment · Topical | 1 Tube | SAR 39.50 | Generic · OTC | GP GRENZACH | Withdrawn by MAH · Not Marketed |
| PANTHENOL | 5 % | Cream · Topical | 1 Tube | SAR 4.90 | Generic · OTC | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Suspended · Not Marketed |
| PANTHENOL | 5 % | Cutaneous liquid · Topical | 1 Bottle | SAR 4.05 | NCE · OTC | THE NILE COMPANY FOR PHARMACEUTICALS AND CHEMICAL IND. | Suspended · Not Marketed |
| PANTHOPHIL 2.5% LOTION | 2.5 % | Lotion · Topical | 1 Tube | SAR 19.30 | Generic · OTC | PHILADELPHIA PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| PANTHOPHIL 5% OINTMENT | 5 % | Ointment · Topical | 1 Tube | SAR 6.00 | Generic · OTC | PHILADELPHIA PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| RECUGEL Eye Gel | 50 mg/g | eye gel · Ophthalmic use | 1 Tube | SAR 30.50 | Generic · OTC | BAUSCH & LOMB GMBH | Invalid · Not Marketed |
Indications — CHI Daman Drug Formulary
ECZEMA
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Dexpanthenol 5% ointment | £6.62 | 100 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 6 Nov 2024 INFUVITE ADULT — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 6 Nov 2024 INFUVITE PEDIATRIC — safety-related labeling change
Labeling sections changed: Use in Specific Populations - US FDA 16 Dec 2020 M.V.I. ADULT — safety-related labeling change
Labeling sections changed: Contraindications; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Nov 2017 M.V.I. ADULT (PHARMACY BULK PACKAGE) — safety-related labeling change
Labeling sections changed: Contraindications; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Nov 2017 M.V.I.-12 — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Dexpanthenol
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.